Credit Suisse Upgrades AbbVie to Hold

Credit Suisse analyst Vamil Divan upgraded AbbVie (NYSE: ABBV) to Hold yesterday and set a price target of $89. The company’s shares closed yesterday at $96.63.

According to, Divan is a 1-star analyst with an average return of -1.3% and a 47.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Eli Lilly & Co.

Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $110.33.

See today’s analyst top recommended stocks >>

Based on AbbVie’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $7.93 billion and net profit of $2.77 billion. In comparison, last year the company earned revenue of $6.94 billion and had a net profit of $1.91 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABBV:

From Our Partners